Trial Profile
Observatory on Treatment Adhesion in Patients Suffering From Hepatitis C Chronic Treated With ViraferonPeg® Injected / Rebetol® in Conjunction With a Psychotherapeutic Assistance Program
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 16 Sep 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 16 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2008 Planned end date changed from 1 Apr 2009 to 1 Jun 2009 as reported by Clinicaltrials.gov.